For Healthcare Professionals
  • For Healthcare Professionals
  • Patient Website
    • Prescribing Information
  • Important Safety Information
  • Medical Information Center
  • Get in Touch
  • Sign Up for Updates
  • REMS Program
  • MM Portfolio
Logo
  • Home
  • Multiple Myeloma
  • Discover the Science
  • Efficacy
  • Final Analysis
  • Safety
  • Dosing and Administration
  • Support and Resources
  • For APPs and Nurses
  • Treatment Locator
Patient Website
  • Prescribing Information
    • TECVAYLI® PRESCRIBING INFORMATIONTECVAYLI® LA INFORMACIÓN DE PRESCRIPCIÓN
  • Important Safety Information
  • Medical Information Center
  • Get in Touch
  • Sign Up for Updates
  • REMS Program
  • MM Portfolio

TECVAYLI® PROVIDED
CLINICALLY MEANINGFUL EFFICACY AT A MEDIAN FOLLOW-UP OF 7 MONTHS1

Study Design
  • Study Design
  • Overall Response Rate
  • Time to First Response and Duration of Response

TECVAYLI®, the first bispecific BCMA × CD3 T-cell engager, was evaluated
in the MajesTEC-1 trial1,2

The efficacy of TECVAYLI® was evaluated in 110 patients with relapsed or refractory multiple myeloma in the single-arm, open-label, multi-center, phase 1/2 MajesTEC-1 trial. Patients had received at least 3 therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1

Primary Endpoint: ORR3 Key Secondary Endpoints: DOR, TTR3

post-treatpost-treat

Patients with a range of characteristics, including those who were heavily pretreated, were studied in MajesTEC-11

  • Median prior lines of therapy: 5 (range: 2-14)
  • 78% of patients had received ≥4 prior lines of therapy
  • 100% of patients had received prior therapy with a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
  • 76% were triple-class refractory (refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody)
  • 81% of patients received prior stem cell transplantation
Patient characteristic chartPatient characteristic chart

In MajesTEC-1, TECVAYLI® delivered an ORR of 61.8%, with 57.3% of patients achieving a deep response of VGPR or better1,4*

Proteasome inhibitor icon

28.2% of patients

experienced ≥CR‡
with TECVAYLI® in the MajesTEC-1 trial

TECVAYLI® provided a median time to first response of

1.2

months1 (range: 0.2-5.5 months)

Median DOR not reached1

(95% CI, 9.0-NE)

61.8%ORR†was demonstrated in the MajesTEC-1 trial
28.2%≥CR‡was demonstrated in the MajesTEC-1 trial

*Efficacy results were based on ORR as determined by the Independent Review Committee (IRC) assessment using International Myeloma Working Group (IMWG) 2016 criteria.

†ORR: sCR+CR+VGPR+PR.

‡≥CR: sCR+CR.

§≥VGPR: sCR+CR+VGPR

BCMA, B-cell maturation antigen; CD3, cluster of differentiation 3; CD38, cluster of differentiation 38; CI, confidence interval; CNS, central nervous system; CR, complete response; del, deletion; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; ORR, overall response rate; PR, partial response; sCR, stringent complete response; t, translocation; TTR, time to response; VGPR, very good partial response.

References:

  1. TECVAYLI® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. U.S. Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Accessed March 7, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma
  3. Moreau P, Garfall A, van de Donk C, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495-505.
  4. Data on file. Janssen Biotech, Inc.
Exclamation point within triangle

Review efficacy data from final analysis

Arrow icon
cta icon

Register to stay up-to-date with important information about TECVAYLI®

Sign Up
Email icon

Connect with a representative from Johnson & Johnson

Get in Touch
Stacked books icon

Access resources to help patients receive TECVAYLI®

Explore Resources
Chat bubble iconChat bubble icon

Need help?

Chat With Medical Information